When breast cancer spreads, it commonly invades the lymph nodes—structures that are part of the body's immune system. Paige's software is designed to find cancer in the lymph nodes that might otherwise be missed, like tiny collections of cancer cells called micrometastases.
Braeden Lichti, a Canadian investor and co-founder of a private investment firm has launched several healthcare companies, talks about how he got his start.
By Catherine Freeland Friday, March 25, 2022 3:43 PM
Social media is a powerful tool for health researchers, but it also has its pitfalls. To make social media an effective part of your study's recruitment and engagement efforts, it's important to avoid making certain mistakes.
By Michael Schroeder Friday, March 25, 2022 2:13 PM
When breast cancer spreads, it commonly invades the lymph nodes—structures that are part of the body's immune system. Paige's software is designed to find cancer in the lymph nodes that might otherwise be missed, like tiny collections of cancer cells called micrometastases.
AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed from Pfizer, to a pivotal test in a rare and potentially fatal lung infection caused by mycobacteria.
Fixing the last mile may not be as sexy as sprinting toward the development of the mRNA vaccines or our first anti-viral treatments, but addressing it is the only way we can improve outcomes for people who need this the most.
The direct recording and analysis of voice ensures that a more diverse range of patients is represented in clinical trials. This is crucial for effective therapeutic outcomes.
In this episode of the MedCity Pivot Podcast, Jonathan Bush talks about his latest venture - Zus Health - through which he wants to help digital health companies share data to create a universal patient off of which new products can be created to serve payers, providers and others with the ultimate goal of improving patient outcomes.
No comments